GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (CHIX:AMGd) » Definitions » Cyclically Adjusted Price-to-FCF

Amgen (CHIX:AMGD) Cyclically Adjusted Price-to-FCF : 15.30 (As of Jun. 05, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Amgen Cyclically Adjusted Price-to-FCF?

As of today (2025-06-05), Amgen's current share price is €248.45. Amgen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €16.24. Amgen's Cyclically Adjusted Price-to-FCF for today is 15.30.

The historical rank and industry rank for Amgen's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

CHIX:AMGd' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 13.2   Med: 18.98   Max: 27.59
Current: 16.1

During the past years, Amgen's highest Cyclically Adjusted Price-to-FCF was 27.59. The lowest was 13.20. And the median was 18.98.

CHIX:AMGd's Cyclically Adjusted Price-to-FCF is ranked better than
77.23% of 325 companies
in the Drug Manufacturers industry
Industry Median: 31.58 vs CHIX:AMGd: 16.10

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Amgen's adjusted free cash flow per share data for the three months ended in Mar. 2025 was €1.676. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €16.24 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Amgen Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Amgen's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Cyclically Adjusted Price-to-FCF Chart

Amgen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.77 16.08 16.75 17.33 14.77

Amgen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.88 18.38 18.67 14.77 17.48

Competitive Comparison of Amgen's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted Price-to-FCF falls into.


;
;

Amgen Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Amgen's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=248.45/16.24
=15.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Amgen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.676/134.9266*134.9266
=1.676

Current CPI (Mar. 2025) = 134.9266.

Amgen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 3.598 100.684 4.822
201509 3.270 100.392 4.395
201512 2.247 99.792 3.038
201603 2.078 100.470 2.791
201606 2.814 101.688 3.734
201609 3.069 101.861 4.065
201612 3.671 101.863 4.863
201703 2.797 102.862 3.669
201706 2.582 103.349 3.371
201709 3.773 104.136 4.889
201712 3.328 104.011 4.317
201803 2.934 105.290 3.760
201806 2.484 106.317 3.152
201809 4.096 106.507 5.189
201812 4.071 105.998 5.182
201903 2.444 107.251 3.075
201906 1.843 108.070 2.301
201909 4.837 108.329 6.025
201912 3.507 108.420 4.364
202003 3.035 108.902 3.760
202006 4.026 108.767 4.994
202009 4.660 109.815 5.726
202012 2.787 109.897 3.422
202103 2.802 111.754 3.383
202106 2.516 114.631 2.961
202109 3.245 115.734 3.783
202112 3.956 117.630 4.538
202203 3.253 121.301 3.618
202206 2.967 125.017 3.202
202209 5.290 125.227 5.700
202212 4.051 125.222 4.365
202303 1.250 127.348 1.324
202306 6.597 128.729 6.915
202309 4.375 129.860 4.546
202312 0.493 129.419 0.514
202403 0.788 131.776 0.807
202406 3.814 132.554 3.882
202409 5.509 133.029 5.588
202412 7.767 133.157 7.870
202503 1.676 134.927 1.676

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Amgen  (CHIX:AMGd) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Amgen Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Amgen's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen Business Description

Industry
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Headlines

No Headlines